Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Friedewald-Estimated Versus Directly Measured Low-Density Lipoprotein Cholesterol and Treatment Implications
Seth S. Martin, Michael J. Blaha, Mohamed B. Elshazly, et al.
Journal of the American College of Cardiology (2013) Vol. 62, Iss. 8, pp. 732-739
Closed Access | Times Cited: 394

Showing 1-25 of 394 citing articles:

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
François Mach, Colin Baigent, Alberico L. Catapano, et al.
European Heart Journal (2019) Vol. 41, Iss. 1, pp. 111-188
Open Access | Times Cited: 6803
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Scott M. Grundy, Neil J. Stone, Alison Bailey, et al.
Circulation (2019) Vol. 139, Iss. 25
Open Access | Times Cited: 5427
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk
François Mach, Colin Baigent, Alberico L. Catapano, et al.
Atherosclerosis (2019) Vol. 290, pp. 140-205
Open Access | Times Cited: 4150
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
Scott M. Grundy, Neil J. Stone, Alison Bailey, et al.
Journal of the American College of Cardiology (2018) Vol. 73, Iss. 24, pp. e285-e350
Open Access | Times Cited: 2084
Statins for the primary prevention of cardiovascular disease
Fiona Taylor, Mark D. Huffman, Ana Filipa Macedo, et al.
Cochrane library (2013) Vol. 2021, Iss. 9
Open Access | Times Cited: 1681
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary
Scott M. Grundy, Neil J. Stone, Alison Bailey, et al.
Journal of the American College of Cardiology (2018) Vol. 73, Iss. 24, pp. 3168-3209
Open Access | Times Cited: 1342
Comparison of a Novel Method vs the Friedewald Equation for Estimating Low-Density Lipoprotein Cholesterol Levels From the Standard Lipid Profile
Seth S. Martin, Michael J. Blaha, Mohamed B. Elshazly, et al.
JAMA (2013) Vol. 310, Iss. 19, pp. 2061-2061
Open Access | Times Cited: 710
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Scott M. Grundy, Neil J. Stone, Alison Bailey, et al.
Circulation (2019) Vol. 139, Iss. 25
Open Access | Times Cited: 683
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines
Salim S. Virani, L. Kristin Newby, Suzanne V. Arnold, et al.
Circulation (2023) Vol. 148, Iss. 9
Open Access | Times Cited: 531
2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
Donald M. Lloyd‐Jones, Pamela B. Morris, Christie M. Ballantyne, et al.
Journal of the American College of Cardiology (2016) Vol. 68, Iss. 1, pp. 92-125
Closed Access | Times Cited: 433
The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk
Pratik B. Sandesara, Salim S. Virani, Sergio Fazio, et al.
Endocrine Reviews (2018) Vol. 40, Iss. 2, pp. 537-557
Open Access | Times Cited: 413
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
Gregory G. Schwartz, Laurence Bessac, Lisa G. Berdan, et al.
American Heart Journal (2014) Vol. 168, Iss. 5, pp. 682-689.e1
Open Access | Times Cited: 398
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia
Eliano Pio Navarese, Michalina Kołodziejczak, Volker Schulze, et al.
Annals of Internal Medicine (2015) Vol. 163, Iss. 1, pp. 40-51
Closed Access | Times Cited: 387
2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
Donald M. Lloyd‐Jones, Pamela B. Morris, Christie M. Ballantyne, et al.
Journal of the American College of Cardiology (2017) Vol. 70, Iss. 14, pp. 1785-1822
Closed Access | Times Cited: 353
2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
Donald M. Lloyd‐Jones, Pamela B. Morris, Christie M. Ballantyne, et al.
Journal of the American College of Cardiology (2022) Vol. 80, Iss. 14, pp. 1366-1418
Open Access | Times Cited: 280
Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study
Renato Quispe, Seth S. Martin, Erin D. Michos, et al.
European Heart Journal (2021) Vol. 42, Iss. 42, pp. 4324-4332
Open Access | Times Cited: 257
LDL cholesterol: controversies and future therapeutic directions
Paul M. Ridker
The Lancet (2014) Vol. 384, Iss. 9943, pp. 607-617
Closed Access | Times Cited: 247
Fasting Triglycerides Predict Recurrent Ischemic Events in Patients With Acute Coronary Syndrome Treated With Statins
Gregory G. Schwartz, Markus Abt, Weihang Bao, et al.
Journal of the American College of Cardiology (2015) Vol. 65, Iss. 21, pp. 2267-2275
Open Access | Times Cited: 245
Lipid lowering with PCSK9 inhibitors
Razvan T. Dadu, Christie M. Ballantyne
Nature Reviews Cardiology (2014) Vol. 11, Iss. 10, pp. 563-575
Closed Access | Times Cited: 226
Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium
Fabian J. Brunner, Christoph Waldeyer, Francisco Ojeda, et al.
The Lancet (2019) Vol. 394, Iss. 10215, pp. 2173-2183
Open Access | Times Cited: 226
Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM
Michel R. Langlois, M. John Chapman, Christa M. Cobbaert, et al.
Clinical Chemistry (2018) Vol. 64, Iss. 7, pp. 1006-1033
Open Access | Times Cited: 225
Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia
Michael J. Koren, Robert P. Giugliano, Frederick J. Raal, et al.
Circulation (2013) Vol. 129, Iss. 2, pp. 234-243
Open Access | Times Cited: 214
Repositioning of the global epicentre of non-optimal cholesterol
Cristina Taddei, Bin Zhou, Honor Bixby, et al.
Nature (2020) Vol. 582, Iss. 7810, pp. 73-77
Open Access | Times Cited: 204
2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia
Salim S. Virani, Pamela B. Morris, Anandita Agarwala, et al.
Journal of the American College of Cardiology (2021) Vol. 78, Iss. 9, pp. 960-993
Open Access | Times Cited: 204
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease
Salim S. Virani, L. Kristin Newby, Suzanne V. Arnold, et al.
Journal of the American College of Cardiology (2023) Vol. 82, Iss. 9, pp. 833-955
Open Access | Times Cited: 203
Page 1 - Next Page

Scroll to top